近日公司及子公司使用闲置自有资金在授权范围内购买了理财产品，现将相 关事项公告如下： | 投资主体 | 受托 | 关联 | 产品名称 | 产品 | 委托理财金 | 起息日 | 到期日 | 预期年 化收益 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | 方 | 关系 | | 类型 | 额（万元） | | | 率 | | 北京诚益通科技有限 | 农商 | 否 | 欣添鑫 | 现金管 | 500.00 | 2025 年 9 月 2 日 | 2025 年 9 月 10 日 | 1.40% | | 公司 | 银行 | | | 理类 | | | | | | 北京诚益通科技有限 | 农商 | 否 | 天天金 | 现金管 | 500.00 | 2025 年 9 月 3 日 | 2025 年 9 月 11 日 | 1.00% | | 公司 | 银行 | | | 理类 | | | | | | 北京诚益通控制技术 | 兴业 | 否 | 兴银稳添利日盈 | 现金管 | 1000.00 | 2025 年 9 月 3 日 | 2025 年 9 月 12 日 | ...

Investment Rating - The report suggests focusing on companies with "technical barriers + clinical landing" as the dual main lines for investment, recommending attention to medical scene integrators and leaders in invasive technology [4]. Core Insights - The brain-computer interface (BCI) industry is driven by both policy and technology, with a market expected to grow from $1.2 billion in 2019 to $2 billion in 2023, and projected to reach $7.63 billion by 2029, indicating a compound annual growth rate (CAGR) of 17.5% from 2024 to 2029 [3][24]. - The medical sector is currently the most mature application area for BCI, with 31 clinical trials planned in 2024 covering various diseases, and the integration of medical and consumer applications is expected to create a dual growth curve [3][54]. - The domestic industry chain is becoming more self-sufficient, with significant advancements in invasive BCI technologies, and several regions are expected to form industrial clusters [4][27]. Summary by Sections Industry Overview - BCI technology is a frontier field at the intersection of life sciences and information technology, creating interactive systems between the brain and external devices [14][16]. - The global BCI market is projected to grow significantly, with a forecasted market size of $7.63 billion by 2029, reflecting a CAGR of 17.5% from 2024 to 2029 [24][25]. - The industry is currently in a technology validation phase, with active investment activities, particularly in China, where over 200 financing events have occurred, totaling nearly $2 billion [27][29]. Policy Guidance - The Chinese government has issued several policies to support the BCI industry, aiming for technological breakthroughs by 2027 and the establishment of a robust industrial ecosystem by 2030 [42][43]. - The regulatory framework is evolving, with ongoing efforts to ensure safety, effectiveness, and ethical compliance in BCI technology [45][47]. Clinical Situation - Stroke is identified as the primary indication for BCI applications, with a significant patient population in need of rehabilitation solutions [54][59]. - The number of clinical trials related to BCI is increasing, with 31 trials registered in 2024, indicating a growing interest in the clinical potential of BCI technologies [65][66].

Core Insights - The company has established a dual-track strategy for its brain-computer interface (BCI) business, focusing on both invasive and non-invasive approaches [1] Non-Invasive Medical Field - In the non-invasive serious medical sector, the company has launched three prototype rehabilitation devices that integrate BCI technology, currently progressing with registration applications [1] - These devices feature modular designs, supporting synchronous collection of EEG, EMG, and ECG signals, and possess precise coordination capabilities with electrical stimulation systems [1] - The devices are designed for flexibility, supporting 8 to 64 channel expansions, and are compatible with mainstream BCI and medical systems, providing reliable support for basic research, neuro-rehabilitation, and BCI application development [1] Consumer Market - In the non-invasive consumer market, the company plans to launch its first batch of prototypes in the first half of 2025, including a next-generation smart EEG headband [2] - This product integrates a self-developed EEG amplification system and intelligent analysis algorithms, enabling high-precision collection and decoding of EEG signals [2] - The headband includes a gamified cognitive training module that adjusts task difficulty based on EEG responses, enhancing user engagement and training effectiveness in attention and memory [2] Invasive Field - In the invasive field, the company is currently focused on technological reserves, with related research in the experimental stage [2] - The company has initiated the construction of a BCI technology research validation center and an animal experiment center, which are crucial for its strategic layout in the BCI field [2] Research Focus - The BCI technology research validation center will focus on cutting-edge theories, key technologies, new materials, and core components in the BCI field, bridging basic mechanism exploration to engineering applications [3] - The animal experiment center will provide in vivo research and application validation for core BCI technologies, equipped for experiments ranging from small rodents to large mammals [3] Financial Performance - In the first half of 2025, the company reported a revenue of 408 million yuan, a year-on-year decrease of 36.65%, and a net profit attributable to shareholders of 51 million yuan, down 38.76% [3] - Revenue breakdown shows that control systems generated 223 million yuan, down 46.12%; rehabilitation medical devices generated 118 million yuan, down 18.10%; and system equipment and others generated 67 million yuan, down 19.50% [3] Market Positioning - The company is leveraging "Longzhijie" to tap into the rehabilitation medical market, which has a comprehensive product line in physical factor therapy and exercise therapy [4]

Core Viewpoint - Chengyitong (300430) has stated that as of September 19, the pledge ratio of shares held by the controlling shareholder and parties acting in concert is 46.49%, which is within a safe and controllable range, and the liquidation price is relatively low, indicating no risk of forced liquidation [1] Group 1 - The current pledge ratio of shares is 46.49% [1] - The company is monitoring risk situations and will disclose relevant information as required [1] - The liquidation price is at a low level, mitigating the risk of forced liquidation [1]

北京市朝阳区东三环中路 5 号财富金融中心 3、11、12 层（100020） 电话：+86 10 6502 8888 传真：+86 10 6502 8866 www.hylandslaw.com 北京浩天律师事务所 关于北京诚益通控制技术集团股份有限公司 2025 年第一次临时股东大会的 法律意见书 致：北京诚益通控制技术集团股份有限公司 根据《中华人民共和国证券法》《中华人民共和国公司法》《上市公司股东 会规则》《北京诚益通控制技术集团股份有限公司章程》（以下简称"《公司章 程》"）的规定，北京本所律师事务所接受北京诚益通控制技术集团股份有限公 司（以下简称"公司"）委托，指派穆铁虎律师、郑玲玲律师（以下简称"本所 律师"）出席公司 2025 年第一次临时股东大会会议，并对本次股东大会会议的 相关事项依法进行见证。 为出具本法律意见书，本所律师审查了公司提供的相关文件资料。现按照律 师行业的业务标准、道德规范和勤勉尽责精神，对公司本次股东大会会议的召集 召开及其他相关事项依法出具并提供如下见证法律意见： 一、本次股东大会的召集、召开程序 经查验，公司本次股东大会是由公司董事会召集召开的。关于召开本次股东 ...

证券代码：300430 证券简称：诚益通 公告编号：2025-046 北京诚益通控制技术集团股份有限公司 2025 年第一次临时股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东大会没有增加、变更、否决议案的情况； 2、本次股东大会不涉及变更前次股东大会决议。 北京诚益通控制技术集团股份有限公司（以下简称"公司"）2025 年第一 次临时股东大会会议通知已于 2025 年 8 月 27 日以公告形式发出。本次会议采取 现场投票和网络投票相结合的方式召开，现将召开会议情况公告如下： 一、会议召开和出席情况 （一）本次股东大会的届次：2025 年第一次临时股东大会 （二）本次股东大会的召集人：公司第五届董事会 （三）本次股东大会现场会议主持人：董事长梁凯先生 （四）会议召开时间： （1）现场会议召开时间：2025年9月12日（星期五）14:00开始。 （2）网络投票时间：2025年9月12日。其中通过深圳证券交易所交易系统进 行网络投票的具体时间为：2025年9月12日9:15-9:25,9:30-11:30，13:00-1 ...

Group 1 - The company Cheng Yitong announced the release of a pledge involving 3.8 million shares by its controlling shareholder, Beijing Liweit Investment Co., Ltd [2]

Group 1 - The company Cheng Yi Tong (300430) announced that it does not provide guarantees to any companies or individuals outside the scope of its consolidated financial statements [1] - Currently, there are no overdue debts, litigation issues, or judgments related to guarantees that the company is liable for [1]

证券代码：300430 证券简称：诚益通 公告编号：2025-044 北京诚益通控制技术集团股份有限公司 关于控股股东部分股权解除质押的公告 公司控股股东保证向公司提供的信息内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。本公司及董事会全体成员保证信息披露的内容真 实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 北京诚益通控制技术集团股份有限公司（以下简称"公司"或"本公司"） 近日接到公司控股股东北京立威特投资有限责任公司（以下简称"立威特"）的 通知，获悉其持有的本公司股份办理了部分股权解除质押业务，具体事项如下： 一、股份质押的基本情况 | 股东 | 是否为控 股股东或 第一大股 | 本次解 除质押 | 占其所 持股份 | 占公司 总股本 | 是否为 | 是否为 补充质 | 质押起 | 质押到 | 质权人 | 质押 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 名称 | 东及其一 致行动人 | 数量（万 股） | 比例 | 比例 | 限售股 | 押 | 始日 | 期日 | | 用途 | | ...

证券代码：300430 证券简称：诚益通 公告编号：2025-045 北京诚益通控制技术集团股份有限公司 关于为上市公司及子公司提供担保的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、融资情况概述 北京诚益通控制技术集团股份有限公司（以下简称"公司"或"诚益通"） 于 2025 年 4 月 23 日召开了第五届董事会第十一次会议，会议审议通过了《关于 预计 2025 年度公司及合并范围内公司申请银行综合授信及项目贷款额度的议案》 《关于预计 2025 年度公司及合并范围内公司担保额度的议案》（公告编号： 2025-020、021），同意公司、子公司及合并报表范围内的子公司、孙公司向银 行及其他金融机构申请合计额度不超过人民币 13.79 亿元的授信等业务，在授权 期限内额度可循环使用，担保总额合计不超过 13.19 亿元。上述议案同时由 2025 年 5 月 15 日召开的 2024 年度股东大会审议通过。 二、融资进展情况 近期，北京诚益通博日鸿智能装备技术有限公司（以下简称"博日鸿"）、 北京诚益通科技有限公司（以下简称"诚益通科技"）、北 ...